Real Estate Sale, Including Osaka HQ, To Raise $347m For Takeda
As part of efforts to raise cash to pay for its acquisition of Shire, Takeda will sell off selected real estate holdings in Japan, including its Osaka HQ, to a mystery buyer.
You may also be interested in...
Takeda saw continued growth for mainstay drugs in what it described as a ‘robust’ last quarter of reporting before the inclusion of Shire, with global blockbuster Entyvio leading the way, but gave away little new on widely anticipated post-deal divestments.
In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.